Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A miniature DNA sequencing device that plugs into a laptop and was developed by Oxford Nanpore has been tested by an open, international consortium, including Oxford University researchers.

The MinION is the smallest high-throughput DNA-sequencing device currently available
The MinION is the smallest high-throughput DNA-sequencing device currently available

The results show that it provides good, repeatable results that can be just as useful as those provided by larger, more expensive devices.

The MinION is a handheld DNA-sequencing device developed by Oxford Nanopore, a spin-out company from the University of Oxford. The smallest high-throughput sequencing system currently available, the device can be plugged into any computer using a USB port, weighs just 90 grams and measures 10 centimetres in length. It works by detecting individual DNA bases that pass through a nanopore — a tiny hole in a membrane. When the DNA bases pass through or near the nanpore, they create a distinctive electrical current, allowing the device to read long DNA sequences in a way that is not possible on most other devices.

Read more

Similar stories

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.

RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Major new study could help protect millions of people with type 2 diabetes from cardiovascular disease

A new study led by the Nuffield Department of Population Health at the University of Oxford will research whether a daily tablet could help protect the millions of people worldwide with type 2 diabetes from developing cardiovascular disease.

Professor Susan Jebb appointed as Chair of the Food Standards Agency

Susan Jebb, Professor of Diet and Population Health in Oxford University’s Nuffield Department of Primary Care Health Sciences, has been appointed as the new Chair of the Food Standards Agency.